Can CV Monitoring Warnings Or REMS Restrictions Save Abbott's Meridia?

Agency presents four regulatory options for the Endocrinologic and Metabolic Drugs Advisory Committee's Sept. 15 review of sibutramine's cardiovascular safety, ranging from continued marketing with no labeling changes to withdrawal.